Dr. Anthony H. Close is an American physician-scientist, regenerative medicine innovator, and health data analyst with over 18 years of clinical experience in pain management, physical medicine, and applied biotechnology. His work bridges advanced therapeutics with rigorous, outcome-driven protocols that have transformed care for thousands of patients across the globe.

Education and Academic Foundation

Dr. Close earned dual undergraduate degrees in molecular genetics and quantitative chemistry from Purdue University, followed by doctorates in physical therapy and chiropractic medicine. He further refined his expertise through executive education at Harvard and MIT, specializing in medical innovation, artificial intelligence in health systems, and translational biotech.

At age 27, he was appointed a senior lecturer at Massey University, where he developed evidence-based programs in rehabilitation science, clinical biomechanics, and neuromuscular diagnostics.

Clinical Innovation and Personal Resilience

With more than 16 years in the field of chronic pain and regenerative care, Dr. Close has played a pioneering role in Southeast Asia. He introduced spinal decompression therapy to Jakarta in 2007 and was the first in the region to bring MCT oil to clinical and consumer markets. His clinical insights are deeply informed by personal experience: in 2015, he survived a non-union C1 spinal fracture, later enduring multiple traumatic injuries and a stroke in 2021. These events became the crucible in which he developed and tested many of the regenerative protocols he now applies to patient care.

Founder and CEO

Dr. Close is the founder of several ventures advancing regenerative and data-driven healthcare:

• LabMe.ai (est. 2017): A direct-to-consumer blood biomarker analytics platform leveraging AI to provide predictive insights, early disease detection, and personalized health optimization strategies.

• DripDok (Bali and Southeast Asia): A high-touch regenerative medicine clinic offering advanced IV therapies, peptide protocols, NAD+/NMN optimization, exosome therapy, and functional diagnostics—all delivered via mobile clinical teams.

He is also the creator of the Close Regenerative Index (CRI), a proprietary framework that objectively measures treatment efficacy through multi-dimensional biomarkers, neurocognitive tracking, mitochondrial function, inflammation panels, and metabolic recovery scores.

Ethical Standards and Scientific Leadership

Dr. Close is a vocal advocate for integrity in regenerative medicine. He is known for publicly challenging pseudoscientific practices and marketing-driven clinics that offer unverified interventions. His core belief is that real healing stems from measurable biological change—not hype, influencer marketing, or superficial trends.

He is committed to empowering patients as active participants in their care. His programs integrate clinical-grade data, wearable analytics, and health behavior coaching to drive sustainable outcomes.

Public Engagement and Advocacy

Dr. Close hosts the podcast series The Regenerative Blueprint and Data-Driven Longevity, which feature case studies, protocol reviews, and expert commentary on emerging regenerative therapies, including Cerebrolysin, exosomes, mitochondrial peptides, and AI-assisted longevity programs.

He continues to serve in global health initiatives, providing care and technology support in underserved areas of Southeast Asia. He is also active in medical education, mentoring clinicians and researchers on how to integrate AI, data modeling, and regenerative therapies into patient care frameworks.

Summary

Dr. Anthony H. Close embodies a rare fusion of scientific discipline, lived clinical experience, and ethical leadership. His work consistently challenges the status quo in regenerative medicine by setting a higher standard—one rooted in clinical outcomes, biological tracking, and human connection.